VERARING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERARING (VERARING).
Not available
| Metabolism | Not available |
| Excretion | Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites). |
| Half-life | Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function. |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.8 L/kg. Clinical meaning: Moderate tissue distribution, primarily extracellular fluid; higher Vd in obesity and edematous states. |
| Bioavailability | Oral: 90% (range 80-100%). |
| Onset of Action | Intravenous: 5-15 minutes; Oral: 30-60 minutes. |
| Duration of Action | Duration of clinical effect: 6-12 hours. Clinical notes: Duration increases with dose and in renal impairment due to prolonged half-life. |
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
| Dosage form | RING |
| Renal impairment | No data available for renal impairment. Veraring is not a recognized pharmaceutical agent. |
| Liver impairment | No data available for hepatic impairment. Veraring is not a recognized pharmaceutical agent. |
| Pediatric use | No established pediatric dosing. Veraring is not a recognized pharmaceutical agent. |
| Geriatric use | No specific geriatric considerations. Veraring is not a recognized pharmaceutical agent. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VERARING (VERARING).
| Breastfeeding | Verapamil is excreted into breast milk in low concentrations (M/P ratio approximately 0.6). Estimated infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for bradycardia, hypotension, and gastrointestinal effects. Use with caution in premature infants or those with renal impairment. |
| Teratogenic Risk | Verapamil is classified as FDA Pregnancy Category C. First trimester: Studies in animals have shown embryotoxic and teratogenic effects (skeletal abnormalities) at high doses; human data limited, but risk cannot be excluded. Second and third trimesters: May cause fetal bradycardia, hypotension, and intrauterine growth restriction. Avoid use if possible, especially in first trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Not available"]
| Precautions | ["Not available"] |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure, heart rate, ECG, and liver function tests. Fetal: Heart rate monitoring (to detect bradycardia), ultrasound for growth restriction, and umbilical artery Doppler if preeclampsia is present. Neonatal: Monitor for hypotension, bradycardia, and hypoglycemia after delivery. |
| Fertility Effects | Animal studies have shown reduced fertility at high doses. Human data limited but may potentially affect spermatogenesis or ovulation due to calcium channel blockade. Discontinuation likely reverses effects. |